ライフサイエンスコーパス: polypharmacy

1 dities and drug-drug interactions in case of polypharmacy.

2 specially in elderly patients and those with polypharmacy.

3 an antiretroviral regimen, increase risk for polypharmacy.

4 scontinuation than those assigned to stay on polypharmacy.

5 inuations entailed returning to the original polypharmacy.

6 tors, including age, sex, comorbidities, and polypharmacy.

7 tic demonstration of rational anticonvulsant polypharmacy.

8 h, syncope in the elderly often results from polypharmacy and abnormal physiologic responses to daily

9 hout statins, although statin users had more polypharmacy and circulatory illnesses than non-users.

10 spite the presence of greater comorbidities, polypharmacy, and altered pharmacokinetics in this age g

11 omplicated by the presence of comorbidities, polypharmacy, and concomitant functional impairment, but

12 omorbid medical illnesses, social isolation, polypharmacy, and factors associated with end-of-life ca

13 eviewing evidence-based approaches to reduce polypharmacy, and outlining the potential benefits of de

14 MCI, clinicians should consider depression, polypharmacy, and uncontrolled cardiovascular risk facto

15 extremely common, but evidence regarding all polypharmacy approaches for schizophrenia from randomize

16 e on evidence regarding the effectiveness of polypharmacy approaches.

17 ddressing medication initiation and managing polypharmacy are central to HF transitional care.

18 The resulting problems of polypharmacy are increase in side effects, drug-drug int

19 imitations, malnutrition, comorbidities, and polypharmacy, as well as social support.

20 were also more likely to report weight loss, polypharmacy, consumption of a special diet, and functio

21 Polypharmacy continues to be a major and poorly understo

22 cancer, we expect that greater attention to polypharmacy could lead to improvements in adverse drug

23 and less than 10 medications, and excessive polypharmacy (EPP) was defined as 10 or more medications

24 licensing trials, the increasing problems of polypharmacy (especially in the elderly), the lack of tr

25 iovascular perspectives with multimorbidity, polypharmacy, frailty, cognitive decline, and other clin

26 , during which drug-drug interactions due to polypharmacy further enhance the risk of adverse effects

27 e monotherapy group lost weight, whereas the polypharmacy group gained weight.

28 MetS patients are strongly exposed to polypharmacy; however, the number of pharmacological com

29 at that patients should be free to return to polypharmacy if an adequate trial on antipsychotic monot

30 s Review examines the existing literature on polypharmacy in advanced cancer and end-of-life settings

31 Given the complex polypharmacy in HF treatment, cognitive deficits may be

32 Polypharmacy in older patients can be minimized by using

33 In view of the apparent burden of polypharmacy in patients with advanced cancer, we expect

34 re has been a recent significant increase in polypharmacy involving antidepressant and antipsychotic

35 Polypharmacy is a well known problem in elderly patients

36 Psychotropic medication polypharmacy is common in psychiatric outpatient setting

37 Polypharmacy is common in the treatment of refractory bi

38 Epidemiology studies have demonstrated that polypharmacy is extremely common, but evidence regarding

39 es, specifically poor compliance to lifelong polypharmacy, lifestyle modifications, and physician ine

40 Morbidity and subsequent polypharmacy occurred more frequently among the patients

41 19 sites) were randomly assigned to stay on polypharmacy or switch to monotherapy by discontinuing o

42 sks and benefits of staying on antipsychotic polypharmacy or switching to monotherapy.

43 ith hospitalization were eating problems and polypharmacy (positive predictive value: 17.9%; sensitiv

44 nal dependence, organ function, comorbidity, polypharmacy, social support, cognitive and/or psychosoc

45 gents identified to date display significant polypharmacy that severely compromises interpretation of

46 The prevalence of polypharmacy (use of >/=5 prescription drugs) increased

47 The increasing trend of psychotropic polypharmacy was mostly similar across visits by differe

48 Although polypharmacy was not associated with higher risk of stro

49 creases in overall prescription drug use and polypharmacy were observed.

50 h 6, 86% (N=48) of those assigned to stay on polypharmacy were still taking both medications, whereas

51 rapy for individuals receiving antipsychotic polypharmacy, with the caveat that patients should be fr

52 examine patterns and trends in psychotropic polypharmacy within nationally representative samples of